Not Signed In -
Letrozole |
Femara |
Image:Letrozole.png Letrozole Systematic (IUPAC) name 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile Identifiers CAS number 112809-51-5 ATC code L02BG04 PubChem 3902 DrugBank APRD01066 Chemical data Formula C17H11N5 Mol. weight 285.303 g/mol Pharmacokinetic data Bioavailability ? Metabolism ? Half life 2 days Excretion ? Therapeutic considerations Pregnancy cat. ? Legal status Routes ? Letrozole (Femara®) i ...
Wikipedia - [full article]
Letrozole Clinical Trials
- Comparison Study of Letrozole Alone or Letrozole With Zoledronic Acid in Early Breast Cancer, Neoadjuvant Therapy
ClinicalTrials.gov Identifier: NCT00247650 - Active, not recruiting
Breast Cancer
- Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer
ClinicalTrials.gov Identifier: NCT00375752 - Recruiting
Breast Neoplasms
- Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00073528 - Active, not recruiting
Metastatic breast cancer; Advanced Breast Cancer
- Letrozole With or Without Tipifarnib in Treating Women With Locally Advanced, Locally Recurrent, or Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00060177 - Active, not recruiting
Breast Cancer
- Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density
ClinicalTrials.gov Identifier: NCT00114270 - Active, not recruiting
Breast Cancer; Osteoporosis
- Phase II Letrozole + Herceptin in Her2neu Positive, ER and/or PR Receptor (+),Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00134680 - Active, not recruiting
Metastatic breast cancer
- Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
ClinicalTrials.gov Identifier: NCT00248170 - Recruiting
Breast Cancer
- Goserelin Plus Letrozole in Premenopausal Patients Versus Letrozole Alone in Postmenopausal Patients With Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00532272 - Recruiting
Breast Cancer; Metastatic
- Letrozole in Preventing Breast Cancer in Postmenopausal Women
ClinicalTrials.gov Identifier: NCT00090857 - Recruiting
Breast Cancer; breast cancer in situ
- Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer
ClinicalTrials.gov Identifier: NCT00107263 - Active, not recruiting
Osteoporosis; stage I breast cancer; stage II breast cancer; stage IIIA breast cancer
- Letrozole With or Without CCI-779 in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00061971 - Active, not recruiting
stage IIIB breast cancer; stage IIIC breast cancer; stage IV breast cancer; recurrent breast cancer
- Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer
ClinicalTrials.gov Identifier: NCT00004251 - Active, not recruiting
endometrial adenosquamous cell carcinoma; endometrial adenocarcinoma; stage IV endometrial cancer; recurrent endometrial cancer
- Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
ClinicalTrials.gov Identifier: NCT00530868 - Not yet recruiting
Breast Cancer; Cancer of the Breast; Breast Neoplasm
- Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00101062 - Active, not recruiting
stage IIIA breast cancer; stage IIIB breast cancer; stage IIIC breast cancer; stage IV breast cancer; recurrent breast cancer
- Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer
ClinicalTrials.gov Identifier: NCT00004205 - Active, not recruiting
stage I breast cancer; stage II breast cancer; stage IIIA breast cancer; breast cancer in situ; recurrent breast cancer; ductal breast carcinoma; ...
- Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery
ClinicalTrials.gov Identifier: NCT00305825 - Active, not recruiting
Breast Cancer
- Letrozole in Postmenopausal Women at Increased Risk for Breast Cancer
ClinicalTrials.gov Identifier: NCT00280930 - Active, not recruiting
Post-Menopausal; Breast Cancer
- Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ
ClinicalTrials.gov Identifier: NCT00290745 - Recruiting
Breast Cancer
- Letrozole Versus Clomifene Citrate for Ovulation Induction
ClinicalTrials.gov Identifier: NCT00478504 - Recruiting
Infertility; Polycystic Ovarian Syndrome
- Effects of Letrozole on Precocious Puberty Due to McCune Albright Syndrome
ClinicalTrials.gov Identifier: NCT00006174 - Recruiting
McCune Albright Syndrome; Polyostotic Fibrous Dysplasia; Precocious Puberty
- Letrozole Treatment in Normal and GnRH Deficient Women
ClinicalTrials.gov Identifier: NCT00351416 - Recruiting
Kallmann's Syndrome; Hypogonadotropic Hypogonadism; Healthy Volunteers
- FRAGRANCE Part A Safety: Study to Find a Genetic Signature of de Novo Resistance to Letrozole
ClinicalTrials.gov Identifier: NCT00199134 - Recruiting
Breast Cancer
- Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density
ClinicalTrials.gov Identifier: NCT00238316 - Active, not recruiting
Breast Cancer
- Breast Neoplasms Study
ClinicalTrials.gov Identifier: NCT00062751 - Active, not recruiting
Breast Neoplasms
- PTK and Letrozole in Post-Menopausal Women With Advanced Breast Cancer
ClinicalTrials.gov Identifier: NCT00263198 - Completed
Breast Neoplasms
- Study of Letrozole plus ZARNESTRA or Placebo in the Treatment of Advanced Breast Cancer
ClinicalTrials.gov Identifier: NCT00050141 - Active, not recruiting
Breast Cancer
- Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer
ClinicalTrials.gov Identifier: NCT00436917 - Active, not recruiting
Breast Cancer; Osteoporosis
- Neoadjuvant Letrozole in Treating Postmenopausal Women With Estrogen-Receptor Positive and/or Progesterone-Receptor Positive Stage II, Stage IIIA, or Stage IIIB Breast Cancer
ClinicalTrials.gov Identifier: NCT00084396 - Recruiting
stage II breast cancer; stage IIIA breast cancer; stage IIIB breast cancer
- Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women With Stage II or Stage III Breast Cancer
ClinicalTrials.gov Identifier: NCT00265759 - Recruiting
Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
- Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
ClinicalTrials.gov Identifier: NCT00332709 - Recruiting
Osteoporosis, Postmenopausal
- Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
ClinicalTrials.gov Identifier: NCT00329940 - Recruiting
Breast Cancer
- Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole
ClinicalTrials.gov Identifier: NCT00376740 - Recruiting
Breast Cancer
- Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer
ClinicalTrials.gov Identifier: NCT00422903 - Recruiting
Hormone-Sensitive Breast Cancer
- Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer
ClinicalTrials.gov Identifier: NCT00498901 - Recruiting
Breast Cancer
- Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer
ClinicalTrials.gov Identifier: NCT00171808 - Recruiting
Endometrial Cancer
- Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer
ClinicalTrials.gov Identifier: NCT00238290 - Recruiting
Breast Cancer
- Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer
ClinicalTrials.gov Identifier: NCT00330317 - Recruiting
Breast Cancer
- Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery
ClinicalTrials.gov Identifier: NCT00541086 - Recruiting
Breast Cancer
- Letrozole (Femara) Plus Imatinib Mesylate (Gleevec) for Breast Cancer Patients
ClinicalTrials.gov Identifier: NCT00338728 - Recruiting
Breast Cancer
- Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma
ClinicalTrials.gov Identifier: NCT00414076 - Recruiting
Uterine Leiomyosarcoma
- Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients
ClinicalTrials.gov Identifier: NCT00504699 - Recruiting
Breast Cancer
- Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00516542 - Recruiting
Breast Cancer
- Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00549822 - Recruiting
Breast Cancer
- Study of Breast Cancer Prevention by Letrozole in High Risk Women
ClinicalTrials.gov Identifier: NCT00579826 - Recruiting
Breast Cancer
- 24 Months of Exemestane or Letrozole to Treat Breast Cancer
ClinicalTrials.gov Identifier: NCT00263913 - Recruiting
Breast Cancer
- RAD001 and Letrozole (Femara) as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women
ClinicalTrials.gov Identifier: NCT00107016 - Completed
Breast Neoplasm
- Changes in Knee Articular Cartilage Volume in Women on Aromatase Inhibitors
ClinicalTrials.gov Identifier: NCT00111241 - Recruiting
Arthralgia
- Letrozole in Patients With Ovarian Tumors
ClinicalTrials.gov Identifier: NCT00505661 - Recruiting
Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
- Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
ClinicalTrials.gov Identifier: NCT00382070 - Recruiting
Breast Cancer
- Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00171847 - Recruiting
Metastatic Breast Cancer
- Trial of Letrozole Plus OSI-774 (Tarceva) in Post-Menopausal Women With Estrogen Receptor (ER) and/or Progesterone Receptor (PR)-Positive Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00179296 - Recruiting
Breast Cancer; Neoplasm Metastasis
- Letrozole and Lapatinib in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery
ClinicalTrials.gov Identifier: NCT00499681 - Recruiting
Breast Cancer
- PREDICT TRIAL- Neoadjuvant Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women Expressing Hormonal Receptors ( ER and PR)
ClinicalTrials.gov Identifier: NCT00237133 - Recruiting
Locally Advanced Breast Cancer
- Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00573755 - Recruiting
Breast Cancer
- Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
ClinicalTrials.gov Identifier: NCT00332852 - Recruiting
Postmenopausal Women With Primary Hormone Receptor Positive Breast Cancer
- Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer
ClinicalTrials.gov Identifier: NCT00461773 - Recruiting
Hormone-Sensitive Breast Cancer; Breast Cancer
- Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer
ClinicalTrials.gov Identifier: NCT00553410 - Recruiting
Breast Cancer
- Phase II Open Label Trial for Post-Menopausal Women with Newly Diagnosed Operable Breast Cancer
ClinicalTrials.gov Identifier: NCT00161291 - Recruiting
Breast Cancer
- Vitamin D Deficiency and Muscle Pain and/or Joint Pain in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage III Breast Cancer
ClinicalTrials.gov Identifier: NCT00416715 - Recruiting
Breast Cancer; Pain
- Testosterone and Its Metabolites in GID
ClinicalTrials.gov Identifier: NCT00146146 - Recruiting
Transsexualism
- Oral CCI-779 Administered in Combination with Letrozole vs. Letrozole Alone in Postmenopausal Women with Locally Advanced or Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00083993 - Terminated
Breast Cancer; Metastases
- Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00014638 - Completed
stage IV breast cancer; recurrent breast cancer
- Chemotherapy in Treating Women With Resected Breast Cancer Following Tamoxifen Therapy
ClinicalTrials.gov Identifier: NCT00003140 - Recruiting
stage I breast cancer; stage II breast cancer; stage IIIA breast cancer
- Phase III Study of Atamestane Plus Toremifene versus Letrozole in Advanced Breast Cancer
ClinicalTrials.gov Identifier: NCT00044291 - Completed
Breast Neoplasms; Neoplasms, Hormone-Dependent
- An Examination of Predictors of Indicators of Response to Letrozole 2.5 Mg
ClinicalTrials.gov Identifier: NCT00291109 - Completed
Breast Cancer
- Optimal Duration of Pre-Operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers
ClinicalTrials.gov Identifier: NCT00535418 - Completed
Breast Cancer
- A Study of Letrozole in the Treatment of Endometrial Cancer
ClinicalTrials.gov Identifier: NCT00333086 - Completed
Recurrent and Metastatic Endometrial Cancer
- The Use of Zoledronic Acid to Prevent Cancer-Treatment Bone Loss in Post-Menopausal Women Receiving Adjuvant Letrozole for Breast Cancer
ClinicalTrials.gov Identifier: NCT00171314 - Completed
Breast Cancer
- The Use of Zoledronic Acid to Prevent Cancer-Treatment Bone Loss in Post-Menopausal Women Receiving Adjuvant Letrozole for Breast Cancer
ClinicalTrials.gov Identifier: NCT00171340 - Completed
Breast Cancer
- Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
ClinicalTrials.gov Identifier: NCT00247663 - Completed
Postmenopausal Women With Advanced Breast Cancer
- Study of High-Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
ClinicalTrials.gov Identifier: NCT00237211 - Completed
Postmenopausal Women With Advanced Breast Cancer
- The CAT Study: Atamestane Plus Toremifene versus Letrozole in Advanced Breast Cancer
ClinicalTrials.gov Identifier: NCT00097344 - Terminated
Breast Neoplasms; Neoplasms, Hormone-Dependent
- A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer
ClinicalTrials.gov Identifier: NCT00171704 - Completed
Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women.
- Study of Safety and Efficacy of Letrozole Monotherapy as Second-Line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-Estrogen Treatment
ClinicalTrials.gov Identifier: NCT00237198 - Completed
Postmenopausal Women With Advanced Breast Cancer
- Letrozole in Metastatic Breast Cancer in Combination With Chemotherapy
ClinicalTrials.gov Identifier: NCT00333047 - Completed
Metastatic Breast Cancer
- Letrozole in the Treatment of Severe and Recurrent Endometriosis
ClinicalTrials.gov Identifier: NCT00240942 - Completed
Severe and Recurrent Endometriosis
- Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole
ClinicalTrials.gov Identifier: NCT00237224 - Terminated
Breast Cancer
- Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer
ClinicalTrials.gov Identifier: NCT00267553 - Terminated
Breast Neoplasms; Neoplasms, Hormone-Dependent
- Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-Therapeutic Risk Assessment
ClinicalTrials.gov Identifier: NCT00241046 - Terminated
Metastatic Breast Cancer
email this page
print this page
bookmark this page
feedback on this page
